Cerity Partners’s Castle Biosciences CSTL Stock Holding History

Cerity Partners’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,138	Closed	-$423K	–	2659
2025 Q1	$423K	Buy	+21,138	New	+$523K	﹤0.01%	1860

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Cerity Partners's CSTL Position: Q2 2025 in Review

Cerity Partners sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 21,138 shares — an estimated $423K sold.

Cerity Partners first reported a position in CSTL in Q1 2025 and held it in 1 quarter. The position peaked at $423K in Q1 2025. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

Cerity Partners reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
Cerity Partners sold 21,138 Castle Biosciences shares in Q2 2025, an estimated $423K.
Cerity Partners first reported a position in Castle Biosciences in Q1 2025 and held it in 1 quarter.
Cerity Partners's Castle Biosciences position peaked at $423K in Q1 2025.
152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Cerity Partners's 13F filing for Q2 2025, filed 13 Aug 2025.